Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-NK cells
- Development stage
- Phase 1
- Lead developer
- Allife Medical Science and Technology
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Parenteral
01
Overview
DC-NK cells is an autologous cell therapy product developed by Allife Medical Science and Technology Co., Ltd. for the treatment of advanced solid tumors. The therapy consists of a combination of dendritic cells (DCs) and natural killer (NK) cells derived from the patient's own peripheral blood. Dendritic cells are professional antigen-presenting cells that stimulate the adaptive immune response by presenting tumor-associated antigens to T cells, while NK cells provide an innate immune response through direct cytotoxicity against tumor cells. This dual-action cell therapy is currently being evaluated in Phase 1 clinical trials, often in combination with PD-1 inhibitors like pembrolizumab (Keytruda), to treat various refractory solid malignancies in both adult and pediatric populations.
- Other names
- Dendritic cell-Natural Killer cell therapyDC-NK cell therapy
Beyond the preview
Go deeper on DC-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-NK cells.